Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service EP ablation cases in Arizona: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 47 | 2,695 | 44% |
| 2020 | 45 | 2,523 | 46% |
| 2021 | 50 | 3,007 |
AF, SVT, and VT catheter ablation. Professional codes (what the surgeon bills): CPT 93656, 93653, 93654; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 35% of the cases CMS names in Arizona; 36 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 165 | 11,552+8.2%/yr | +8.2%/yr | 2.9 | 0% | 21,900 in 2030+11%/yr |
| Washington | 49 | 2,678 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| LAA occlusion & loop recorders | 106 | 4,739+15%/yr | +15%/yr | 5.62.3× | 41% | 7,950 in 2030+9%/yr |
| Pacemaker, ICD & CRT implantation |
EP ablation in every state, and its device makers · Every procedure market in Arizona · Every state · Compare with California
| 2024 |
| 3,909 |
| 54% |
| 2025 est. | ≈ 4,360 | – |
| 2026 est. | ≈ 4,700 | – |
| 49% |
| 2022 | 56 | 3,136 | 51% |
| 2023 | 57 | 3,268 | 53% |
| 2024 | 62 | 3,909 | 54% |
| 2025 from claims | – | 4,362 4,003–4,615 | 55% |
| 2026 forecast | – | 4,702 4,137–5,426 | 55% |
| 2027 forecast | – | 5,051 4,318–6,019 | 56% |
| 2028 forecast | – | 5,426 4,528–6,644 | 56% |
| 2029 forecast | – | 5,828 4,760–7,309 | 57% |
| 2030 forecast | – | 6,260 5,015–8,022 | 57% |
In 2025, 12% inpatient hospital, 88% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| +2.4%/yr |
| 2.9 |
| 0% |
| 4,000 in 2030+6.9%/yr |
| Colorado | 47 | 2,229+6.8%/yr | +6.8%/yr | 3.8 | 0% | 4,850 in 2030+14%/yr |
| Utah | 20 | 1,253+6.8%/yr | +6.8%/yr | 4.8 | 0% | 2,180 in 2030+9.7%/yr |
| Oregon | 25 | 1,089+4.8%/yr | +4.8%/yr | 2.1 | 0% | 1,910 in 2030+9.9%/yr |
| Nevada | 16 | 764+6.9%/yr | +6.9%/yr | 2.2 | 0% | 1,620 in 2030+13%/yr |
| Montana | 10 | 763+16%/yr | +16%/yr | 3.6 | 0% | 1,730 in 2030+15%/yr |
| Idaho | 10 | 646+5.8%/yr | +5.8%/yr | 2.7 | 0% | 1,310 in 2030+12%/yr |
| New Mexico | 8 | 559+9.8%/yr | +9.8%/yr | 2.0 | 0% | 1,040 in 2030+11%/yr |
| Alaska | 4 | 397+5.8%/yr | +5.8%/yr | 3.3 | 0% | 740 in 2030+11%/yr |
| 85 |
| 4,095−2.6%/yr |
| −2.6%/yr |
| 5.71.5× |
| 26% |
| 4,390 in 2030+1.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Johnson & Johnson MedTech leads with 44% of company spending on these surgeons in 2025, −10 pts on 2024.
In 2025, 8 companies reported engagement with Arizona’s surgeons worth $300K in consulting, speaking, meals and travel tied to these products, about $4,832 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 102 clearances and approvals in the category, 5 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.